Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 48 results for bortezomib

  1. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [ID4026]

    In development [GID-TA10918] Expected publication date: 11 December 2024

    Technology appraisal guidance
    In development

  2. Bortezomib monotherapy for relapsed multiple myeloma (TA129)

    Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma in adults.

    Technology appraisal guidance
    Published
    23 October 2007
    View recommendations

    Sections for TA129

  3. Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)

    Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for treating multiple myeloma in adults.

    Technology appraisal guidance
    Published
    27 July 2011
    View recommendations

    Sections for TA228

  4. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.

    Technology appraisal guidance
    Published
    6 June 2023
    View recommendations

    Sections for TA897

  5. Bortezomib for previously untreated mantle cell lymphoma (TA370)

    Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.

    Technology appraisal guidance
    Published
    16 December 2015
    View recommendations

    Sections for TA370

  6. Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)

    Evidence-based recommendations on selinexor (Nexpovio) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.

    Technology appraisal guidance
    Published
    15 May 2024
    View recommendations

    Sections for TA974

  7. Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)

    Evidence-based recommendations on pomalidomide (Imnovid) for multiple myeloma previously treated with lenalidomide and bortezomib in adults.

    Technology appraisal guidance
    Published
    11 January 2017
    View recommendations

    Sections for TA427

  8. Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)

    Evidence-based recommendations on bortezomib (Velcade) for treating multiple myeloma before chemotherapy and stem cell transplant in adults.

    Technology appraisal guidance
    Published
    23 April 2014
    View recommendations

    Sections for TA311

  9. Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)

    Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults.

    Technology appraisal guidance
    Published
    26 June 2019
    View recommendations

    Sections for TA586

  10. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212

    In development [GID-TA11203] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  11. Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA603)

    NICE is unable to make a recommendation on lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma in adults because Celgene did not provide an evidence submission.

    Technology appraisal guidance
    Published
    25 September 2019

    Sections for TA603

  12. Myeloma: diagnosis and management (NG35)

    This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

    NICE guideline
    Last updated
    25 October 2018
    View recommendations

    Sections for NG35

  13. Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) (TA771)

    NICE is unable to make a recommendation on daratumumab (Darzalex) with bortezomib, melphalan and prednisone for untreated multiple myeloma because Janssen did not provide an evidence submission.

    Technology appraisal guidance
    Published
    9 February 2022

    Sections for TA771

  14. Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) (TA453)

    NICE is unable to make a recommendation about the use in the NHS of bortezomib for treating multiple myeloma after second or subsequent relapse because no evidence submission was received from Janssen-Cilag.

    Technology appraisal guidance
    Published
    5 July 2017

    Sections for TA453

  15. Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA602)

    NICE is unable to make a recommendation on pomalidomide (Imnovid) with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma in adults because Celgene did not provide an evidence submission.

    Technology appraisal guidance
    Published
    25 September 2019

    Sections for TA602